NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

RespireRx Pharmaceuticals Inc (OTCQB: RSPI)

 
RSPI Technical Analysis
1
As on N/A RSPI STOCK Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

RSPISTOCK Price

Open N/A Change Price %
High N/A 1 Day N/A N/A
Low N/A 1 Week N/A N/A
Close N/A 1 Month N/A N/A
Volume N/A 1 Year N/A N/A
52 Week High N/A | 52 Week Low N/A
 
OTCQB USA Most Active Stocks
VPLM 0.02 %
BMIX 0.01 %
CYDY 0.14 %
NWBO 0.39 %
SYAXF 0.02 %
ALPP 3.56 0.00%
ALPP 3.56 0.00%
SHMP 0.01 %
VKIN 0.23 0.00%
AREB 0.51 %
 
OTCQB USA Top Gainers Stocks
EMMLF 0.89 8800.00%
EWLUD 0.45 275.00%
HCAND 0.02 100.00%
TRYPF 0.06 50.00%
TUMIF 0.09 50.00%
EXDI 0.82 38.98%
NVMDF 0.27 35.00%
NVMDF 0.27 35.00%
GYRRF 0.24 33.33%
DSMTF 0.04 33.33%
 
OTCQB USA Top Losers Stocks
MCURF 0.03 -40.00%
NOCSF 0.13 -23.53%
GENH 0.14 -22.22%
EMPR 19.46 -20.73%
EMPR 19.46 -20.73%
CURR 0.08 -20.00%
IFNY 0.04 -20.00%
NIKLF 0.05 -16.67%
UBMRD 0.56 -15.15%
NPDCF 0.06 -14.29%
 
 
RSPI
Daily Charts
RSPI
Intraday Charts
Whats New @
Bazaartrend
RSPI
Free Analysis
 
RSPI Important Levels Intraday
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
 
RSPI Forecast July 2024
4th UP Forecast
3rd UP Forecast
2nd UP Forecast
1st UP Forecast
1st DOWN Forecast
2nd DOWN Forecast
3rd DOWN Forecast
4th DOWN Forecast
 
RSPI Weekly Forecast
4th UP Forecast
3rd UP Forecast
2nd UP Forecast
1st UP Forecast
1st DOWN Forecast
2nd DOWN Forecast
3rd DOWN Forecast
4th DOWN Forecast
 
RSPI Forecast2024
4th UP Forecast
3rd UP Forecast
2nd UP Forecast
1st UP Forecast
1st DOWN Forecast
2nd DOWN Forecast
3rd DOWN Forecast
4th DOWN Forecast
 
 
RSPI Other Details
Segment EQ
Market Capital 1826011.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
RSPI Address
RSPI
 
RSPI Latest News
 
Your Comments and Response on RespireRx Pharmaceuticals Inc
 
RSPI Business Profile
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system's endogenous cannabinoid receptors for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, SCI, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey. Address: 126 Valley Road, Glen Rock, NJ, United States, 07452
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service